Benzinga | Oct 1, 2021 06:06AM EDT

BrainStorm Cell Therapeutics To Present Phase 2 Data Results At Congress of the European Committee for Treatment and Research in Multiple Sclerosis Oct. 14 At 10:45 a.m. EDT

BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that a scientific abstract titled "Phase 2 Safety and Efficacy Study of Intrathecal MSC-NTF cells in Progressive Multiple Sclerosis" will be presented in an oral presentation at the fully digital 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). The presentation will be delivered by Jeffrey Cohen, M.D. Director of Experimental Therapeutics at the Cleveland Clinic Mellen Center for MS.

The presentation will feature results from a Phase 2 trial that evaluated three repeated intrathecal administrations of NurOwn(r) (MSC-NTF cells), each given 2 months apart, as a treatment for progressive multiple sclerosis (MS). The trial achieved the primary endpoint of safety and tolerability, and improvements were observed in secondary endpoints spanning neurologic function, cognition, and biomarkers. Abstracts are now available online: https://ectrims2021.abstractserver.com/program/#/results.

Presentation details:

Session Title: Free Communications 2 - Treatment trials - Immunomodulation

Session Date: October 14th 2021

Presenting Time: 4:45 p.m. - 5:45 p.m. CEST

"We are excited to communicate the potential of our proprietary cell therapy NurOwn(r) in progressive MS at the 37th Congress of ECTRIMS," said Chaim Lebovits, Chief Executive Officer of BrainStorm. "We appreciate the contributions of the study participants and investigators who have advanced our understanding of NurOwn as an important therapeutic option for patients with progressive MS and are grateful that Dr Jeffrey Cohen will be giving this important oral presentation on behalf of the study investigators and BrainStorm."

Ralph Kern, MD MHSc, President and Chief Medical Officer of BrainStorm added, "It is a great privilege to share our Phase 2 progressive MS clinical trial results with leading MS experts from around the globe at the 37th Congress of ECTRIMS. The scientific exchange at ECTRIMS will be critical to inform our ongoing efforts to advance our proprietary cell therapy in progressive MS."